0001703057falseVancouverBC2215 Yukon StreetVancouverBC00017030572025-02-182025-02-180001703057dei:FormerAddressMember2025-02-182025-02-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 18, 2025
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue
Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 8.01 Other Events.

Effective February 18, 2025, Dr. Veronique Lecault has transitioned from Chief Operating Officer (COO) to Chief Technology Officer (CTO). The change in Dr. Lecault’s title was mutually agreed upon and was not due to any disagreement with the Company on any matter relating to its operations, policies, or practices. Dr. Lecault’s roles and responsibilities as COO will transfer to her role as CTO. Dr. Lecault will continue as a Director on the Company’s Board of Directors.

The Company is not filling the position of COO, and the position will be dissolved.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 18, 2025ABCELLERA BIOLOGICS INC.
 
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)

v3.25.0.1
Cover
Feb. 18, 2025
Entity Addresses [Line Items]  
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Document Type 8-K
Entity Registrant Name AbCellera Biologics Inc.
Document Period End Date Feb. 18, 2025
Entity Incorporation, State or Country Code A1
Entity File Number 001-39781
Entity Address, Postal Zip Code V5Y 1G6
Entity Central Index Key 0001703057
Amendment Flag false
Entity Address, Address Line One 150 W 4th AvenueVancouver, BC
City Area Code (604)
Local Phone Number 559-9005
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares
Trading Symbol ABCL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Former Address  
Entity Addresses [Line Items]  
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Address Line One 2215 Yukon Street
AbCellera Biologics (NASDAQ:ABCL)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 AbCellera Biologics 차트를 더 보려면 여기를 클릭.
AbCellera Biologics (NASDAQ:ABCL)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 AbCellera Biologics 차트를 더 보려면 여기를 클릭.